Table 2.
Smoking duration in current and past smokers and time since smoking cessation in past smokers in ORAL Surveillance
| Current smokers | Past smokers | |||
| Tofacitinib N=811 |
TNFi N=352 |
Tofacitinib N=605 |
TNFi N=322 |
|
| Smoking Duration (years) | ||||
| Mean (SD) | 32.7 (13.1) | 31.9 (13.2) | 37.2 (13.0) | 39.9 (12.2) |
| Median (Range) | 35.0 (0.02, 67.00) | 34.2 (0.02, 69.00) | 39.0 (0.00, 69.00) | 41.0 (1.00, 70.00) |
| Smoking duration levels*, % (n) | ||||
| >10 years | 91.4% (741) | 91.2% (321) | 96.2% (582) | 98.4% (317) |
| >5–10 years | 4.4% (36) | 3.7% (13) | 2.3% (14) | 0.9% (3) |
| >0–5 years | 4.2% (34) | 5.1% (18) | 1.5% (9) | 0.6% (2) |
| Time since smoking cessation levels, % (n) | ||||
| ≥10 years | – | – | 61.5% (372) | 71.7% (231) |
| <10 years | – | – | 38.5% (233) | 28.3% (91) |
| <5 years | – | – | 21.8% (132) | 15.2% (49) |
| <1 year | – | – | 5.6% (34) | 3.1% (10) |
*Information on smoking duration was missing on eight patients (two current and six past smokers) treated with tofacitinib and five patients (one current and four past smokers) treated with TNFi.
n, number of patients with characteristic; TNFi, tumour necrosis factor inhibitor.